Acorah Software Products - Accounts Production 16.2.850 false true false 9 October 2024 30 September 2025 30 September 2025 16006769 Dr Nisha Rishi S Arujuna iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 16006769 2024-10-08 16006769 2025-09-30 16006769 2024-10-09 2025-09-30 16006769 frs-core:CurrentFinancialInstruments 2025-09-30 16006769 frs-core:Non-currentFinancialInstruments 2025-09-30 16006769 frs-core:ComputerEquipment 2025-09-30 16006769 frs-core:ComputerEquipment 2024-10-09 2025-09-30 16006769 frs-core:ComputerEquipment 2024-10-08 16006769 frs-core:ShareCapital 2025-09-30 16006769 frs-core:RetainedEarningsAccumulatedLosses 2025-09-30 16006769 frs-bus:PrivateLimitedCompanyLtd 2024-10-09 2025-09-30 16006769 frs-bus:FilletedAccounts 2024-10-09 2025-09-30 16006769 frs-bus:SmallEntities 2024-10-09 2025-09-30 16006769 frs-bus:AuditExempt-NoAccountantsReport 2024-10-09 2025-09-30 16006769 frs-bus:SmallCompaniesRegimeForAccounts 2024-10-09 2025-09-30 16006769 frs-bus:Director1 2024-10-09 2025-09-30 16006769 frs-bus:Director1 2024-10-08 16006769 frs-bus:Director1 2025-09-30 16006769 frs-countries:EnglandWales 2024-10-09 2025-09-30
Registered number: 16006769
NRA Dermatology Ltd
Unaudited Financial Statements
For the Period 9 October 2024 to 30 September 2025
Sharpe Medical Accounting Ltd
NRA Dermatology Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
NRA Dermatology Ltd
Balance Sheet
As At 30 September 2025
Balance Sheet
Registered number: 16006769

| 30 September 2025
--- | ---
| Notes | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 1,498
|  |  | 1,498
CURRENT ASSETS
Debtors | 5 | 12,156 |
Cash at bank and in hand |  | 27,974 |
|  | 40,130 |
Creditors: Amounts Falling Due Within One Year | 6 | (10,808 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 29,322
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 30,820
Creditors: Amounts Falling Due After More Than One Year | 7 |  | (437 )
NET ASSETS |  |  | 30,383
CAPITAL AND RESERVES
Called up share capital | 8 |  | 1
Profit and Loss Account |  |  | 30,382
SHAREHOLDERS' FUNDS |  |  | 30,383

Page 1
Page 2
NRA Dermatology Ltd
Balance Sheet (continued)
As At 30 September 2025
For the period ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Dr Nisha Rishi S Arujuna Director
21/11/2025

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
NRA Dermatology Ltd
Notes to the Financial Statements
For the Period 9 October 2024 to 30 September 2025
Notes to the Financial Statements
1. General Information
NRA Dermatology Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 16006769 . The registered office is Normanby Gateway, Lysaghts Way, Scunthorpe, Lincolnshire, DN15 9YG.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is recognised when a company gains entitlement to receive income from a third party.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment | 20% on WDV

2.4. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the period, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
Page 3
Page 4
NRA Dermatology Ltd
Notes to the Financial Statements (continued)
For the Period 9 October 2024 to 30 September 2025
3. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
4. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 9 October 2024 | -
Additions | 1,498
As at 30 September 2025 | 1,498
Net Book Value
As at 30 September 2025 | 1,498
As at 9 October 2024 | -

5. Debtors

| 30 September 2025
--- | ---
| £
Due within one year
Trade debtors | 6,486
Other debtors | 5,670
| 12,156

6. Creditors: Amounts Falling Due Within One Year

| 30 September 2025
--- | ---
| £
Trade creditors | (1 )
Other creditors | 1,059
Taxation and social security | 9,750
| 10,808

7. Creditors: Amounts Falling Due After More Than One Year

| 30 September 2025
--- | ---
| £
Other loans | 437

Page 4
Page 5
NRA Dermatology Ltd
Notes to the Financial Statements (continued)
For the Period 9 October 2024 to 30 September 2025
8. Share Capital

| 30 September 2025
--- | ---
| £
Allotted, Called up and fully paid | 1

9. Directors Advances, Credits and Guarantees
Included within Debtors are the following loans to directors:

| As at 9 October 2024 | Amounts advanced | Amounts repaid | Amounts written off | As at 30 September 2025
--- | --- | --- | --- | --- | ---
| £ | £ | £ | £ | £
Dr Nisha Rishi S Arujuna | - | 11,137 | 5,467 | - | 5,670

The above loan is unsecured, interest free and repayable on demand.
Page 5